Alessandra Calabresi

Summary

Affiliation: University of Foggia
Country: Italy

Publications

  1. ncbi request reprint Male breast cancer in an HIV-infected patient: a case report
    Alessandra Calabresi
    Department of Infectious Diseases, University of Brescia, Italy
    Infez Med 20:284-7. 2012
  2. doi request reprint Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir
    Daria Gotti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    HIV Clin Trials 13:245-55. 2012
  3. ncbi request reprint Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors
    Giuseppe Lapadula
    Clinic for Infectious Diseases and Tropical Medicine, University of Brescia, Brescia, Italy
    Antivir Ther 13:601-5. 2008
  4. pmc Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
    Emanuele Focà
    Infectious Diseases Department, University of Brescia, Brescia, Italy
    BMC Infect Dis 12:38. 2012
  5. doi request reprint Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era
    Laura Albini
    Department of Infectious Diseases, University of Brescia, Brescia, Italy
    AIDS Res Hum Retroviruses 29:1097-104. 2013
  6. doi request reprint Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy
    Daria Gotti
    University Division of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Patient Care STDS 27:259-65. 2013
  7. doi request reprint A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz
    Laura Albini
    Department of Materno Infantile e Tecnologie Biomediche, Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    J Acquir Immune Defic Syndr 59:18-30. 2012
  8. ncbi request reprint Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV
    Eugenia Quiros-Roldan
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 13:341-8. 2008

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Male breast cancer in an HIV-infected patient: a case report
    Alessandra Calabresi
    Department of Infectious Diseases, University of Brescia, Italy
    Infez Med 20:284-7. 2012
    ....
  2. doi request reprint Increase in standard cholesterol and large HDL particle subclasses in antiretroviral-naïve patients prescribed efavirenz compared to atazanavir/ritonavir
    Daria Gotti
    Institute of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    HIV Clin Trials 13:245-55. 2012
    ..Lipoprotein-particle subclasses may also have an effect, but comparative data after standard HAART regimens are limited...
  3. ncbi request reprint Prevalence and risk factors for etravirine resistance among patients failing on non-nucleoside reverse transcriptase inhibitors
    Giuseppe Lapadula
    Clinic for Infectious Diseases and Tropical Medicine, University of Brescia, Brescia, Italy
    Antivir Ther 13:601-5. 2008
    ..Prevalence and factors associated with etravirine (EW) resistance mutations among patients failing on first-generation non-nucleoside reverse transcriptase inhibitors (NNRTI) merit investigation...
  4. pmc Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
    Emanuele Focà
    Infectious Diseases Department, University of Brescia, Brescia, Italy
    BMC Infect Dis 12:38. 2012
    ..Lastly, the effect of tenofovir on 1,25-(OH)₂ vitamin D is uncertain...
  5. doi request reprint Burden of non-AIDS-defining and non-virus-related cancers among HIV-infected patients in the combined antiretroviral therapy era
    Laura Albini
    Department of Infectious Diseases, University of Brescia, Brescia, Italy
    AIDS Res Hum Retroviruses 29:1097-104. 2013
    ..98, p=0.057). HIV-infected men showed a 2-fold increased risk of non-virus-related NADCs compared to the general population. However, the use of cART appeared to be beneficial in protecting against the development of these malignancies...
  6. doi request reprint Clinical characteristics, incidence, and risk factors of HIV-related Hodgkin lymphoma in the era of combination antiretroviral therapy
    Daria Gotti
    University Division of Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    AIDS Patient Care STDS 27:259-65. 2013
    ..37 cells/μL for controls, p<0.0001). Compared with the general population, HIV-infected patients showed an increased risk for developing HL. The risk of HIV-HL increased significantly in the first months after cART initiation...
  7. doi request reprint A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz
    Laura Albini
    Department of Materno Infantile e Tecnologie Biomediche, Institute of Infectious and Tropical Diseases, University of Brescia, Italy
    J Acquir Immune Defic Syndr 59:18-30. 2012
    ..There is lack of data on GFR estimated by these methods in patients on highly active antiretroviral therapy...
  8. ncbi request reprint Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV
    Eugenia Quiros-Roldan
    Institute for Infectious and Tropical Diseases, University of Brescia, Brescia, Italy
    Antivir Ther 13:341-8. 2008
    ..The efficacy of long-term hepatitis B virus (HBV) treatment with tenofovir (TDF) in relation to lamivudine (LMV) resistance in HIV patients failing on LMV deserves further investigations...